Pharma market access strategy Archives - Business Intelligence

Tag: Pharma market access strategy

Pharma secondary packaging market

Infiniti’s Competitive Intelligence Solution for A Prominent Company in The Pharma Secondary Packaging Market: Exploring Key Packaging Innovations And competitive landscape Insights

In pharmaceuticals, secondary packaging constitutes the packaging which does not come in direct contact with the dosage form. Pharma secondary packaging is becoming widely adopted and essential as they offer critical functionalities, such as, for physical and barrier protection, secondary containment, adherence to regulations, and consumer safety. It also creates a buffer and protects primary packages from each other during transportation.

Business challenge

A prominent pharmaceutical company headquartered in San Francisco, CA sought to explore the changing trends in the secondary pharma packaging market by focusing the research on major design/technology innovations and best practices adopted by leading players in the pharma secondary packaging market. Through the engagement, the client wanted to support their future packaging developments and track industry trends over time. By leveraging Infiniti’s competitive intelligence solution, the pharmaceutical company wanted to understand the competitor landscape in the US and European pharma secondary packaging market, new features of secondary packaging being incorporated by competitors, product portfolio descriptions, and competitor strategies to promote adherence.   

Want comprehensive insights into the market drivers, challenges, key industry players, and more in the pharma secondary packaging market? Request a complimentary proposal.

Our Approach

Experts at Infiniti Research started by delving deeply into the pharma secondary packaging market transformation over the past decade in the US and Europe. This involved a well-balanced combination of primary and secondary research. Telephonic discussions were undertaken with over 45 respondents with expertise in the development, sales, marketing, and usage of products and services related to secondary packaging market such as pharmaceutical packaging specialists, packaging engineers, and packaging development experts. The secondary research undertaken by our analysts included comprehensive research materials from company websites, industry news CPA, HCPC, CHPA, packaging digest, and public database.

Through extensive competitive intelligence study and research methodologies, experts at Infiniti Research were able to identify the top pharma secondary packaging designs that are predominantly used. This includes medication adherence packaging, extended labels, and increasing use of sustainable materials in pharma secondary packaging. Furthermore, Infiniti’s competitor landscape assessment also identified some of the key competitors in the US and Europe, their respective packaging initiatives, and critical initiative undertaken to promote adherence.

With a focus to ensure product integrity, better manufacturing efficiency, and enhancing customer satisfaction, experts at Infiniti Research have identified that companies are developing innovative technologies such as thermochromic indicators and contemporary cartons designs. Furthermore, with Infiniti’s recommendation, the client adopted robotics and process automation that significantly improves production output, lowers operating cost, and enhances worker safety.

Business Impact

By leveraging Infiniti’s competitive intelligence solution, the client was able to successfully track their key market competitors and identify some of the most innovative and viable trends in the pharma secondary packaging market. Apart from this client was also able to:

  • Increase investments on their primary and secondary packaging lines by adopting technologies which result in faster turn-around time, fewer errors, and higher adaptability to incorporate and reproduce design changes
  • Collaborate with the CPO to formulate innovative packaging designs which are senior-friendly, child- resistant, medication adherence promoting, and offers unique dispensing mechanisms
  • Expedite early market entry for biologics and personalized medicine by identifying advancements such as 3D printing in pharmaceutical packaging
  • Reduce operational cost by 30% within this first quarter by adopting RPA into packaging operations
  • Focus on packaging designs that are cost-effective and have shorter production turnaround times
  • Incorporate adherence features in the secondary packaging design to help practitioners promote the use of the drugs to the patients
  • Build an effective planning and production process to minimize packaging errors and prevent product recalls, saving the company over $1.2 million within six months

For similar engagements for your business, get in touch with an industry expert

pharma M&A

Capturing Value from Pharma M&A: Critical Considerations for Success

The pharmaceutical industry is one of the major sectors that is actively involved in huge mergers and acquisition (M&A) deals, both in terms of numbers of deals and the amount of money spent. Most companies in the sector, especially the big pharma consider pharma M&A as a major factor to bolster innovation and overall growth. A recent research by our pharma industry experts shows that revenues coming from innovations sourced outside of Big Pharma is currently stands at over 45%. Over the years, several large, game-changing deals have continuously and profoundly changed the competitive landscape of the sector, while smaller yet significant transactions remain an integral part of pharma industry operations.

Why Pharma M&A is a driver of strategic repositioning?

Pharma M&A has become a common practice for companies that have non-diverse pipelines or have top revenue drugs that are nearing patent expiration and subsequent generic erosion. According to industry experts at Infiniti Research, some of key reasons why companies favor pharma M&A include:

  • The critical size requirements across various market segments have increased exponentially over the years. At this rate, it becomes nearly impossible for a single company for companies to survive on their own. This made strategic pharma M&A a necessity for most companies
  • Large mergers in the pharma industry allow bundling of sub-critical businesses, and thereby change the culture and to build new platforms
  • Another motivation for pharma M&A is to capture annual cost synergies by scaling up

For more insights on our portfolio of services for companies in the pharma industry

Consideration for successful M&A

Achieving Successful Integration Post Pharma M&A

Approximately only 60% of pharma merger deals succeed in the long run. A successful merger is one wherein the resulting company achieves the strategic intentions driving the merger when the deal was initially formed. Mergers that fail often show traits including focusing more attention on back-office integration, cost control, and systems consolidation.

Creating business synergies

Revenue increases during pharma M&A can often more difficult to achieve and take longer than expected. During pharma mergers and acquisitions teams must develop strategies such as the degree to which the existing portfolios need to be rationalized, how teams can be used to increase efficiency, how salesforce can be consolidated to remove overlap, and how the projects of each of the brands can be enhanced.

Defining the integration strategy

The successful integration of two companies largely depends on having a consistent approach with strategic intent. Guiding principles, priorities, and governance must reflect the logic behind the merger. A reliable integration strategy must be efficient in articulating both financial and nonfinancial goals, as well as risk-mitigation strategies.

Request a free proposal for more insights on how we can support your pharma M&A efforts.

Pharma secondary packaging market

Answering FAQs on Pharmaceutical Logistics

An overview of the global pharmaceutical logistics market

Keeping pharmaceutical products undamaged and therapeutically effective during their journey to the market can often prove to be an arduous and complex task. Once outside the sterile manufacturing and packaging facility, the risk of product contamination during the pharmaceutical logistics process can be high.  The handling of temperature-controlled pharmaceutical products during the pharma logistics process is a complicated business irrespective of the mode of transport and presents unique challenges. Furthermore, the pharmaceutical industry is heavily segmented, resulting in an increased level of M& activity in the sector. The pharmaceutical industry is also experiencing a geographic shift in its major production locations and sales markets. Asia and South America, in particular, are becoming increasingly attractive markets for companies in the sector. But these markets are regarded as the most challenging in terms of supply chain and pharmaceutical logistics operations. As technology and innovation in the pharmaceutical space mature, we can expect advanced and risk-free pharma supply chain and logistics processes in the near future. In this article, Infiniti’s thought leaders answer some key questions relating to pharmaceutical logistics.

Cutting costs and increasing capacity is one of the greater challenges facing the pharmaceutical industry. Looking for ways to achieve this? Request a free proposal from our industry experts.

What are some of the biggest pharmaceutical logistics challenges facing companies currently?

Supply chain visibility is one of the key challenges facing pharmaceutical logistics. This could become a serious challenge especially for companies that intensively deal with regulatory affairs. Pharma manufacturers must overcome this barrier as better supply chain visibility into pharmaceutical logistics as it helps enhance shipment lead times, analyze customer sales projections can drive efficiency benefits, reduce inventories, and improve fulfillment rates. Furthermore, challenges related to increased globalization are presenting suppliers, consumers, and regulatory bodies in the pharmaceutical logistics space with increased risk and uncertainties.

What are some of the key region-specific insights on pharmaceutical logistics?

Pharma logistics are highly mature in Western Europe and the United States. In the future, we can expect least number of supply chain issues from Nordic countries. At present, emerging markets including China and Southeast Asia, the Middle East, South America, and Eastern Europe look highly lucrative for growth in the pharmaceutical industry. As the demand for modern medical treatments and healthcare products rises in these emerging and ‘high-potential’ nations, pharmaceutical companies are moving to unfamiliar territories and cultures and also learning about the accompanying supply chain challenges in these regions. These roadblocks include unstable regulatory environment and underdeveloped logistics infrastructure.

The world of pharmaceutical logistics is a complex, challenging, and ever evolving sphere. But with the right strategies in place you can capitalize on the right opportunities and stay successful. Get in touch with us to know more about how we our solutions can help your business.

 Why is it beneficial for pharma companies to outsource logistics services?

Most of the top benefits of outsourcing pharmaceutical logistics and supply chain include cost benefits. Outsourcing transportation and warehousing help life sciences companies to considerably reduce their overall costs. However, outsourcing does not completely solve supply chain visibility challenges. Moreover, factors including the rise of generics, the fall of the blockbuster model, and a sharp increase in R&D cost are putting companies in the pharmaceutical industry under pressure to bring down costs. Outsourcing logistics is an effective way to reduce the overall costs and also reduce the total time-to-market.

What criteria are most important while choosing a logistics service provider?

Consistency and reliability of services are two key traits that are paramount characteristics to consider while selecting a pharmaceutical logistics service provider. The provider’s industry experience and reputation in terms of safety and security of material handling should also be taken into consideration. Top pharmaceutical companies are already using outsourcing as a strategic part of the company’s overall business strategy especially to establish consistency and efficiency across the international supply chain network. To ensure continued partnership with pharmaceutical companies, logistics service providers must safeguard the confidentiality of the proprietary knowledge, prove its reliability in services, offer continuous improvements, and comply with the regulatory requirements of their clients.

Learn more about our portfolio of services

regenerative medicines

Identifying Key Regenerative Medicine Manufacturing Challenges

Regenerative medicine is currently the hive of innovation in modern science with far-reaching benefits for big pharma, healthcare systems, and patient outcomes. We can expect a rapid pace of development in the US regenerative medicine market over the next decade. Some of the key factors fueling demand include the increasing investments in R&D activities and the rising incidence of chronic diseases in the country. Leading vendors have enhanced their R&D investments to develop innovative medical therapies, which is driving the overall growth of the market. Furthermore, M&A and strategic alliances among vendors will have a significant impact on the overall market growth and innovation. Nevertheless, the actual delivery of regenerative medicines has proven to be rather challenging with several roadblocks to commercially viable therapies that are capable of catering to unmet clinical needs. In this article, based on a series of discussions with industry analysts at Infiniti Research, we highlight some of the most relevant and pressing manufacturing challenges in regenerative medicine products.

Regenerative medicine

The promise of regenerative medicines requires an innovative look at the complete product lifecycle, including the development of an efficient distribution network. Planning to venture into this space? Request a free proposal for comprehensive insights about the market.

Regenerative medicine manufacturing challenges

Manufacturing expense

Cell therapy manufacturing processes are generally highly expensive. Scaling up from limited laboratory facilities to automated systems for bulk production will largely be based on cost, therefore impeccable financial and time planning become vital. As a first-generation technology, stakeholders we can expect greater stakeholder tolerance for higher pricing, but this will only be for a limited time period. 

Design quality

After collecting sufficient evidence of clinical effectiveness of regenerative medicines, bioreactor technologies are considered for the manufacture of regenerative medicine products. But even minor process changes at this stage will require new validation of the product performance. So, in the case of automation, robots manually reproduce the existing inefficient manual processes due to which the products are often based on obsolete technologies. As a result, the manufacture of regenerative medicines sometimes misses the opportunity to improve their quality by innovating process design.

The personalization and unique requirements of regenerative medicines require manufacturers to provide increased focus on precision and accuracy of processes. Get in touch with an expert from Infiniti research to identify gaps in your existing processes and bridge them with viable business strategies.

Biomaterials challenges

Challenges relating to biomaterials is mostly concerned with their selection than the manufacturing. The trends in material selection will eventually have a major impact on the manufacturing process. As traditional synthetic biodegradable polymers and a few bioactive ceramics that have been manufactured through conventional routes are no longer considered ideal, attention is now being turned toward biomaterials that have more relevant biological properties. But since they have critical nanostructural features, and may involve self-assembly and environmental responsiveness, they may not be compatible with normal top-down manufacturing and therefore could require changes in the production process.

Supply chain challenges

The clinical supply chains required to deliver regenerative medicines therapies are arguably the most complex the industry has seen so far, even more so than for biologic medicine. At present, while billions of dollars are being spent on regenerative medicine research and clinical studies, resources are yet to be allocated to the management and delivery of innovative medical therapies at scale. Furthermore, progress by the pharma industry in coming into compliance with the FDA’s regulations for regenerative medicines has been slow. This makes the process of bringing regenerative medicines at scale to the market even more challenging.  

Learn more about our portfolio of solutions

Pharmaceutical market access

Enhancing Market Share by 33% for a Pharma Company – Pharmaceutical Market Access Strategy

Pharmaceutical Market Access Strategy

With healthcare becoming a priority for governments in several countries, the pharmaceutical industry seems to have a bright future. However, due to the rising healthcare costs, payers are demanding insights into a new drug’s cost-effectiveness compared with alternative drugs and generics. Consequently, pharmaceutical companies are under the need to revamp the way they develop and market drugs. As such, leveraging pharmaceutical market access strategy is becoming imperative for pharma companies during the early stages of drug development in order to tackle the market access related-issues.

Our pharmaceutical market access strategy can help you to identify barriers to new market entry and achieve huge commercial success for your new drug. Request a FREE proposal today!

Business Challenge

The client is a pharmaceutical company based out of Germany.

Our client, a pharmaceutical company, wanted to expand their operations to the United States. However, the client noted that market entry to the US pharma industry was highly challenging due to the need to accommodate rising costs and the proliferation of competing drugs in the same therapeutic areas. In addition, the growth of the generic segment and the advent of biosimilar drugs in the United States were increasing challenges for the company.

As the client had already failed in their attempt to launch a new drug in the US market, they did not want to take a chance. They approached the experts at Infiniti Research during the early stages of drug development to leverage their expertise in offering pharmaceutical market access strategy.

2

With Infiniti’s pharmaceutical market access strategy, the client also wanted to:

#1: Gather insights for the R&D team

While developing a new drug, there are numerous factors that need to be considered by the R&D team. The R&D team must determine if the amount invested in drug development is worthwhile. Also, the team must ensure that newly launched drugs easily clear clinical trials and are capable of surviving competition from other branded drugs or generics. In addition, as the clinical pathways and treatment models change very frequently in the US, it is crucial for pharma companies to gather comprehensive insights into the market landscape and competitors before advancing pipeline drugs to the next level. With Infiniti’s pharmaceutical market access strategy, the client wanted help in gathering insights into healthcare needs in the US and develop drugs accordingly.

#2: Gather insights for HEOR (Health Economics and Outcomes Research) and marketing team

As value-based reimbursement was gaining more traction in the US healthcare system, the HEOR team in pharma companies are compelled to develop a sound product commercialization strategy in comparison to their competitors. Also, the team must evaluate the potential for a new drug in the market for the coming years. The client’s HEOR teams wanted help in developing a sound product marketing strategy that will aid their drug’s market access and commercialization goals. Therefore, with Infiniti’s pharmaceutical market access strategy, they wanted to thoroughly analyze the marketing and sales strategies of the top pharmaceutical companies in the US. In addition, by leveraging Infiniti’s pharmaceutical market access strategy, the client wanted to understand the marketing channels to focus on to reach their end-users.

#3: Set a sound pricing strategy

As pharma companies in the US were no longer the sole decision-makers when it comes to setting drug prices, they were compelled to consider payers’ opinions in order to achieve optimal commercial success for their drugs. With Infiniti’s pharmaceutical market access strategy, the client wanted to analyze the different pricing strategies in the US pharmaceutical industry and set the right price for their new drugs.

Our pharmaceutical market access strategy can help you to navigate the complex market challenges and yield huge profits. Contact us today!

Solutions Offered

1As a part of the pharmaceutical market access strategy, the experts at Infiniti Research conducted a product research engagement. In this phase of the pharmaceutical market access engagement, the experts helped the client to analyze the complete product development lifecycle, trade-offs, and gather insights on product-specific revenues to boost value proposition.

The next phase of the pharmaceutical market access approach involved a marketing strategy engagement. In this phase of the pharmaceutical market access approach, the experts conducted qualitative and quantitative market research to help the client gather comprehensive insights into the market landscape and competitive landscape. Also, this phase of the pharmaceutical market access strategy helped the client to identify the best marketing channels to focus on to reach their end-users. Also, the experts helped the client to devise sound commercialization strategies to achieve huge success for their products in the US pharma market.

Our pharmaceutical market access approach also involved price analysis engagement, where the experts analyzed the payers’ opinions in the US pharma market and the top pharma companies’ pricing strategies. This phase of the pharmaceutical market access strategy helped the client to set the right price for their new drugs based on the market demand.

Results Obtained

Infiniti’s pharmaceutical market access strategy helped the client to develop a new drug meeting the market demand and payer’s requirement. The newly launched drug cleared the clinical trials in the initial attempt.

The insights obtained from Infiniti’s pharmaceutical market access strategy also helped the client to devise a sound commercialization strategy for their new drug. Also, the experts helped the client in setting the right price for the product.

Within one year of new drug launch, the client was able to meet their revenue goal and enhance market share by 33%.

3

Request for more information to know more about the benefits of leveraging pharma market access strategy for your business.

Pharmaceutical manufacturing

Winning in Emerging Markets: What Big Pharma Companies Must Do

Emerging markets are highly promising and offer a plethora of opportunities for pharmaceutical companies. As a result, there is an unprecedented increase in the number of companies in the life sciences industry that are turning to emerging markets such as Brazil, India, and China to set up their businesses. Pharma industry experts at Infiniti Research believe that big pharma companies that are innovative and advanced in terms of manufacturing, logistics and distribution, and understanding customer needs are more likely to gain an edge over the others in these coveted markets. Despite several efforts, some big pharma companies often fail to gain a major foothold in these regions. This issue occurs due to several reasons. Sometimes, new entrants in the big pharma market discover that operating and selling in emerging markets can be challenging due to market access requirements including manufacturing, logistics, and supply chain can be complex. Furthermore, unfavorable regulatory environment, dynamic pricing and reimbursement practices, and talent management challenges also pose major challenges for big pharma companies in emerging markets.

In this article, Pharma industry experts at Infiniti Research share some of the key strategies that big pharma companies can use to succeed in new and emerging markets.

Growth strategies for big pharma companies are increasingly dependent on expansion into emerging markets. Request a free proposal to know how we can help support your market expansion plan into emerging markets.

How big pharma can compete effectively in emerging markets

Big pharma companiesOne of the primary steps in establishing and executing a growth strategy for big pharma companies involve identifying commonalities across markets. These commonalities must support cost-effective approaches while taking into account the unique regulatory constraints and consumer attributes of different regions. Here are three key approaches for big pharma companies to capitalize on attractive opportunities in emerging markets.

Group customers into clusters

Customer submarkets in emerging countries can be identified within a national or regional market by analyzing and grouping consumers who have common health needs. Creating customer clusters in emerging markets will help big pharma companies to identify various customer challenges in the market and create tailored solutions to cater to the needs of these groups.

Identify cross-border commonalities

Constricting emerging market entry to national boundaries is a common mistake that big pharma companies make. An approach that is too focused on national or regional boundaries could mean that customer similarities across markets are not being sufficiently leveraged to create solutions that can move across borders. Identifying cross-border insights can enable big pharma companies to serve groups or clusters of customers more effectively and efficiently.

Timely and cost-effective execution

Given the fact that most life sciences companies operate in functional silos, executing solutions across markets in a timely and cost-effective manner could prove challenging. Therefore, big pharma companies must focus on creating a single, coherent strategy rather than trying to coordinate separate strategies. Two capabilities that are especially critical when planning the rapid execution of an emerging-market strategy include developing the ability to understand and to get close to the customer and improving the risk management capabilities.

Learn more about Infiniti’s solutions for big pharma companies

Pharma manufacturing

Finding the Future of Pharma Manufacturing – Strategies to Reduce Costs and Boost Efficiency

The growing rate of the aging population with significant unmet needs is creating a high demand for pharma manufacturing companies. However, pharma manufacturing companies are also facing headwinds from unattractive pricing and volume expansion across all regions, growing size and bargaining power of payers, the emerging biological patent cliff, and the growing competitive pressure. Amidst these challenges pharmaceutical manufacturers are seeking to reduce operational costs and streamline cycle time within R&D. Below, our pharma industry experts have listed out some key strategies that pharma manufacturing companies can use to gain efficiency and enhance their R&D process.

Heads of R&D at major pharmaceutical companies agree that there is a critical need to substantially increase the number of innovative new medicines, while eliminating inefficiencies that drive up R&D costs. Request a free proposal to know how we help pharma manufacturers achieve this.

Partial outsourcing

Outsourcing at least a small part of research and development processes to emerging markets and low-cost centers can help pharma manufacturers to considerably reduce their overall costs. Companies in the pharma sector can take inspiration from other significant industries to relocate certain operations to areas where labor costs are cheaper. However, some pharma manufacturing companies are often skeptical about outsourcing R&D as it carries a heavy risk. This is one of the prime reasons why experts suggest shifting only non-core activities to low-cost centers.

Business process management

Companies in pharma manufacturing can gain increased efficiency by relying on business process management. Redundancies in processes can be reduced through automation and optimization. This can also help pharma manufacturers reduce their time to market and enable regulatory compliance with R&D phase of a new drug such as simplifying clinical trial processes, minimizing errors, and creating a collaborative research environment.

Looking for solutions to address your key business challenge? Get in touch with an expert for unparalleled business insights.

Eliminate ‘non-value adding’ activities

This is also often termed as lean process improvement. This method has proven effective for increasing efficiency and reducing operating costs for companies across various industries. Lean techniques can help pharma manufacturing companies to improve workplace efficiency within laboratories, while the focus on eliminating unnecessary steps can help speed up certain processes to reduce cycle time.

Strategic partnerships

This is not a strictly process improvement technique, but an external strategic alliance can help pharmaceuticals manufacturing companies to streamline and improve operations that one company operating in isolation may not succeed in doing.

Gain more insights on Infiniti’s solutions for the pharma industry

Close
Infiti Logo

Hello there!

Contact us to know more about our cost-effective custom market research offerings to support efficient market penetration, new product launch, and devise strategies to monitor and outperform your competitors.

Cookie Policy

The Site uses cookies to record users' preferences in relation to the functionality of accessibility. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice